_version_ 1784740748032212992
author Martin-Blondel, Guillaume
Marcelin, Anne-Genevieve
Soulié, Cathia
Kaisaridi, Sofia
Lusivika-Nzinga, Clovis
Dorival, Céline
Nailler, Laura
Boston, Anaïs
Melenotte, Cléa
Cabié, André
Choquet, Christophe
Coustillères, François
Martellosio, Jean-Philippe
Gaube, Géraldine
Trinh-Duc, Albert
Ronchetti, Anne-Marie
Pourcher, Valerie
Chauveau, Marie
Lacombe, Karine
Peiffer-Smadja, Nathan
Housset, Pierre
Perrot, Aurore
Pialoux, Gilles
Martin, Aurélie
Dubee, Vincent
Devaux, Mathilde
Frey, Jérôme
Cazanave, Charles
Liblau, Roland
Carrat, Fabrice
Yordanov, Youri
author_facet Martin-Blondel, Guillaume
Marcelin, Anne-Genevieve
Soulié, Cathia
Kaisaridi, Sofia
Lusivika-Nzinga, Clovis
Dorival, Céline
Nailler, Laura
Boston, Anaïs
Melenotte, Cléa
Cabié, André
Choquet, Christophe
Coustillères, François
Martellosio, Jean-Philippe
Gaube, Géraldine
Trinh-Duc, Albert
Ronchetti, Anne-Marie
Pourcher, Valerie
Chauveau, Marie
Lacombe, Karine
Peiffer-Smadja, Nathan
Housset, Pierre
Perrot, Aurore
Pialoux, Gilles
Martin, Aurélie
Dubee, Vincent
Devaux, Mathilde
Frey, Jérôme
Cazanave, Charles
Liblau, Roland
Carrat, Fabrice
Yordanov, Youri
author_sort Martin-Blondel, Guillaume
collection PubMed
description
format Online
Article
Text
id pubmed-9254651
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-92546512022-07-05 Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2 Martin-Blondel, Guillaume Marcelin, Anne-Genevieve Soulié, Cathia Kaisaridi, Sofia Lusivika-Nzinga, Clovis Dorival, Céline Nailler, Laura Boston, Anaïs Melenotte, Cléa Cabié, André Choquet, Christophe Coustillères, François Martellosio, Jean-Philippe Gaube, Géraldine Trinh-Duc, Albert Ronchetti, Anne-Marie Pourcher, Valerie Chauveau, Marie Lacombe, Karine Peiffer-Smadja, Nathan Housset, Pierre Perrot, Aurore Pialoux, Gilles Martin, Aurélie Dubee, Vincent Devaux, Mathilde Frey, Jérôme Cazanave, Charles Liblau, Roland Carrat, Fabrice Yordanov, Youri J Infect Letter to the Editor The British Infection Association. Published by Elsevier Ltd. 2022-10 2022-07-05 /pmc/articles/PMC9254651/ /pubmed/35803386 http://dx.doi.org/10.1016/j.jinf.2022.06.033 Text en © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Martin-Blondel, Guillaume
Marcelin, Anne-Genevieve
Soulié, Cathia
Kaisaridi, Sofia
Lusivika-Nzinga, Clovis
Dorival, Céline
Nailler, Laura
Boston, Anaïs
Melenotte, Cléa
Cabié, André
Choquet, Christophe
Coustillères, François
Martellosio, Jean-Philippe
Gaube, Géraldine
Trinh-Duc, Albert
Ronchetti, Anne-Marie
Pourcher, Valerie
Chauveau, Marie
Lacombe, Karine
Peiffer-Smadja, Nathan
Housset, Pierre
Perrot, Aurore
Pialoux, Gilles
Martin, Aurélie
Dubee, Vincent
Devaux, Mathilde
Frey, Jérôme
Cazanave, Charles
Liblau, Roland
Carrat, Fabrice
Yordanov, Youri
Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
title Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
title_full Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
title_fullStr Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
title_full_unstemmed Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
title_short Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
title_sort sotrovimab to prevent severe covid-19 in high-risk patients infected with omicron ba.2
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254651/
https://www.ncbi.nlm.nih.gov/pubmed/35803386
http://dx.doi.org/10.1016/j.jinf.2022.06.033
work_keys_str_mv AT martinblondelguillaume sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT marcelinannegenevieve sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT souliecathia sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT kaisaridisofia sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT lusivikanzingaclovis sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT dorivalceline sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT naillerlaura sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT bostonanais sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT melenotteclea sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT cabieandre sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT choquetchristophe sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT coustilleresfrancois sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT martellosiojeanphilippe sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT gaubegeraldine sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT trinhducalbert sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT ronchettiannemarie sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT pourchervalerie sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT chauveaumarie sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT lacombekarine sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT peiffersmadjanathan sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT houssetpierre sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT perrotaurore sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT pialouxgilles sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT martinaurelie sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT dubeevincent sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT devauxmathilde sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT freyjerome sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT cazanavecharles sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT liblauroland sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT carratfabrice sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2
AT yordanovyouri sotrovimabtopreventseverecovid19inhighriskpatientsinfectedwithomicronba2